The Psychedelic Substance Supports Microbiome and Normalizes Serotonin Levels
Last month, SafeMinds Shares reported on the stir psilocybin was creating in the financial world. Market analysts and investors were viewing the psychedelic as a potential revolutionary autism treatment. The autism treatment market is currently valued at $3.2 billion and is desperately lacking in drug therapies. A new treatment could prove very profitable for investors. During a recent interview with scientist and researcher Marvin Hausman, M.D., additional scientific reasons were revealed which show how psilocybin may be key to treating autism. Dr. Hausman, an immunologist with more than 30 years of drug research experience, explains that elevated levels of serotonin are found in individuals with autism. Ninety percent of serotonin is produced in the small intestine, an area where the microbiome lives. Microbiome problems and gut disorders are linked with autism. Dr. Hausman believes that psilocybin has the ability to fix microbiome dysfunction in the small intestine where serotonin is produced. This process could theoretically result in the normalization of serotonin levels for individuals with autism. Correcting serotonin levels should lead to a reduction of symptoms in affected individuals. This process is what makes psilocybin such an exciting new possible treatment.
